Emergent BioSolutions (EBS) Non-Current Debt (2010 - 2026)

Emergent BioSolutions' Non-Current Debt history runs 17 years deep, the most recent figure standing at $573.6 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 13.84% year-over-year to $573.6 million; the TTM figure through Mar 2026 stood at $573.6 million (down 13.84% YoY), while the FY2025 annual figure was $572.1 million, down 13.8% from the prior year.
• Non-Current Debt was $573.6 million for Q1 2026 at Emergent BioSolutions, roughly flat from $572.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $1.0 billion in Q3 2022 to a low of $446.5 million in Q4 2023.
• Historically, Non-Current Debt has averaged $601.6 million across 5 years, with a median of $573.6 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Non-Current Debt slumped 56.57% in 2023, then surged 49.4% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $448.5 million in 2022, then retreated by 0.45% to $446.5 million in 2023, then surged by 48.65% to $663.7 million in 2024, then retreated by 13.8% to $572.1 million in 2025, then climbed by 0.26% to $573.6 million in 2026.
• The last three Non-Current Debt figures came in at $573.6 million (Q1 2026), $572.1 million (Q4 2025), and $663.1 million (Q3 2025), per Business Quant data.